Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Thorax
|
June 2, 2025
Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening
Andrew W Creamer, Carolyn Horst, Ruth Prendecki, et al.
Thorax
|
July 21, 2022
Telephone risk-based eligibility assessment for low-dose CT lung cancer screening
Jennifer L Dickson, Helen Hall, Carolyn Horst, et al.
Lancet (London, England)
|
March 31, 2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, et al.
Chest
|
June 30, 2026
Symptom prevalence and impact on lung cancer risk in the SUMMIT study
Monica L Mullin, Andrew W Creamer, Amyn Bhamani, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 30, 2022
Utilisation of primary care electronic patient records for identification and targeted invitation of individuals to a lung cancer screening programme
Jennifer L Dickson, Helen Hall, Carolyn Horst, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 9, 2023
The SUMMIT Study: Utilising a written 'Next Steps' information booklet to prepare participants for potential lung cancer screening results and follow-up
Amyn Bhamani, Carolyn Horst, Fanta Bojang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 29, 2022
The reporting of pulmonary nodule results by letter in a lung cancer screening setting
Jennifer L Dickson, Amyn Bhamani, Samantha L Quaife, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 7, 2019
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer
John D Fenwick, David B Landau, Angela T Baker, et al.
The Lancet. Oncology
|
June 28, 2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, et al.
BMJ Open Respiratory Research
|
September 11, 2025
Differentiating clinically important interstitial lung abnormalities in lung cancer screening
Brintha Selvarajah, Amyn Bhamani, Mehran Azimbagirad, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Thorax
|
June 2, 2025
Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening
Andrew W Creamer, Carolyn Horst, Ruth Prendecki, et al.
Thorax
|
July 21, 2022
Telephone risk-based eligibility assessment for low-dose CT lung cancer screening
Jennifer L Dickson, Helen Hall, Carolyn Horst, et al.
Lancet (London, England)
|
March 31, 2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, et al.
Chest
|
June 30, 2026
Symptom prevalence and impact on lung cancer risk in the SUMMIT study
Monica L Mullin, Andrew W Creamer, Amyn Bhamani, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 30, 2022
Utilisation of primary care electronic patient records for identification and targeted invitation of individuals to a lung cancer screening programme
Jennifer L Dickson, Helen Hall, Carolyn Horst, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 9, 2023
The SUMMIT Study: Utilising a written 'Next Steps' information booklet to prepare participants for potential lung cancer screening results and follow-up
Amyn Bhamani, Carolyn Horst, Fanta Bojang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 29, 2022
The reporting of pulmonary nodule results by letter in a lung cancer screening setting
Jennifer L Dickson, Amyn Bhamani, Samantha L Quaife, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 7, 2019
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer
John D Fenwick, David B Landau, Angela T Baker, et al.
The Lancet. Oncology
|
June 28, 2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, et al.
BMJ Open Respiratory Research
|
September 11, 2025
Differentiating clinically important interstitial lung abnormalities in lung cancer screening
Brintha Selvarajah, Amyn Bhamani, Mehran Azimbagirad, et al.
Page
of 4